# Bio-Path Holdings (BPTH) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/BPTH
## Company Profile
- Ticker: BPTH
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Nucleic Acid Drugs, Oncology
## Stock Data
- Close: 0.0002 USD
- Market cap: Not available USD
- Last updated: 2026-10-08
## Business Overview
### Antisense Oncology Company
Bio-Path Holdings develops liposomal antisense therapies for cancer. Its DNAbilize platform packages short DNA molecules in neutral lipid nanoparticles to reduce production of disease-driving proteins.
### Prexigebersen in Acute Myeloid Leukemia
Prexigebersen, or BP1001, targets GRB2, an adaptor protein involved in cancer-cell signaling. The candidate is being studied with established leukemia therapies in patients with acute myeloid leukemia and related blood cancers.
### BP1002 BCL-2 Program
BP1002 targets BCL-2, a protein that helps cancer cells evade programmed cell death. Clinical development focuses on relapsed or refractory acute myeloid leukemia and other hematologic malignancies.
### BP1003 STAT3 Program
BP1003 is designed to reduce STAT3 expression, a signaling protein implicated in tumor growth, survival, and immune evasion. The program extends DNAbilize into solid tumors.
## Why The Stock Is Moving

Current closing-price context is not available for BPTH.

## Recent News
- 2025-06-09 11:00 EST — [Bio-Path Holdings to Present at Life Sciences Virtual Investor Forum](https://biopharmsignal.com/news/BPTH/bio-path-holdings-to-present-at-life-sciences-virtual-investor-forum-6c80073e) — Source: Bio-Path Holdings
- 2025-06-03 11:00 EST — [Bio-Path Holdings Provides Clinical and Operational Update](https://biopharmsignal.com/news/BPTH/bio-path-holdings-provides-clinical-and-operational-update-945f6be3) — Source: Bio-Path Holdings
- 2025-05-22 20:30 EST — [Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025](https://biopharmsignal.com/news/BPTH/bio-path-holdings-to-host-corporate-update-conference-call-on-may-29-2025-7d0815d0) — Source: Bio-Path Holdings
- 2025-05-01 11:00 EST — [Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients](https://biopharmsignal.com/news/BPTH/bio-path-holdings-achieves-third-pre-clinical-milestone-confirming-potential-of--a70a6183) — Source: Bio-Path Holdings
- 2025-03-28 11:00 EST — [Bio-Path Holdings Reports Full Year 2024 Financial Results](https://biopharmsignal.com/news/BPTH/bio-path-holdings-reports-full-year-2024-financial-results-d19bcd3b) — Source: Bio-Path Holdings